Company · REGN
Regeneron
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
9
9 still marketed
Novel approvals
8
Approvals since 2021
34
Originals and new uses
Phase 3 trials
105
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Pasatru approved NovelPriority reviewOrphanAug 19, 2026
- Dupixent new use Apr 22, 2026
- Eylea Hd new use Apr 2, 2026
- Dupixent new use Priority reviewFeb 23, 2026
- Eylea Hd new use Priority reviewNov 19, 2025
- Libtayo new use Priority reviewOct 29, 2025
- Praluent new use OrphanOct 9, 2025
- Libtayo new use Priority reviewOct 8, 2025
- Evkeeza new use Breakthrough therapyPriority reviewOrphanSep 25, 2025
- Dupixent new use Priority reviewOrphanJun 18, 2025
Drugs in development (41)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- REGN7508CenvacibartPhase 312 trials
Regeneron · Atrial Fibrillation (AF), Venous Thromboembolism (VTE), Venous Thromboembolism
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- OlatorepatideHS-20094Phase 38 trials
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Type 2 Diabetes, Overweight or Obesity, Overweight or Obesity Without Diabetes
- OdronextamabREGN1979, OrdsponoPhase 37 trials
Regeneron · Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), Relapsed/Refractory Follicular Lymphoma
- CemdisiranALN-CC5Phase 35 trials
Regeneron · Paroxysmal Nocturnal Hemoglobinuria, Generalized Myasthenia Gravis, Age-related Macular Degeneration (AMD)
- MibavademabREGN4461Phase 35 trials
Regeneron · Generalized Lipodystrophy, Functional Hypothalamic Amenorrhea, FHA
- REGN9933amrecibartPhase 35 trials
Regeneron · Atrial Fibrillation (AF), Peripheral Artery Disease (PAD), Venous Thromboembolism (VTE)
- ALN-CIDEBPhase 34 trials
Regeneron · Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, MASLD
- CMP 001VidutolimodPhase 32 trials
Pfizer · Advanced Malignancies, NSCLC, Ovarian Cancer
- REGN1908FreneslerbartPhase 32 trials
Regeneron · Allergic Conjunctivitis
- REGN1909MevonlerbartPhase 32 trials
Regeneron · Allergic Conjunctivitis
- REGN5713BremzalerbartPhase 31 trial
Regeneron · Allergic Conjunctivitis
- REGN5715AtisnolerbartPhase 31 trial
Regeneron · Allergic Conjunctivitis
- UbamatamabREGN4018Phase 24 trials
Regeneron · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- REGN10597PD-1-IL2Ra-IL2 immunotherapyPhase 23 trials
Regeneron · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- REGN5678NezastomigPhase 23 trials
Regeneron · Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
- REGN7075marlotamigPhase 23 trials
Regeneron · Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
- ALN-PNPPhase 22 trials
Regeneron · Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Healthy Volunteers
- Fianlimab [Fixed ]Phase 22 trials
Regeneron · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- REGN4336Phase 22 trials
Regeneron · Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
- REGN5459Vonsetamig, BCMAxCD3Phase 22 trials
Regeneron · Chronic Kidney Disease (CKD), Relapsed Multiple Myeloma, Refractory Multiple Myeloma
- REGN7544baloncibartPhase 22 trials
Regeneron · Postural Orthostatic Tachycardia Syndrome (POTS), Sepsis-Induced Hypotension
- ALN-6457ALN-PRNPPhase 21 trial
Regeneron · Prion Disease
- BNT116Phase 21 trial
Regeneron · Advanced Non-Small Cell Lung Cancer
- FDC fianlimabPhase 21 trial
Regeneron · Head and Neck Squamous Cell Carcinoma (HNSCC)
Recruiting Phase 3 trials
Largest first.
- Stroke and Systemic Embolism Prevention in Adult Participants With Atrial FibrillationPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07626411 · 15,364 participants (planned) · Start Aug 10, 2026 · Primary completion Sep 11, 2029
Drug: REGN7508; Apixaban and 1 more · For: Atrial Fibrillation (AF)
Sites: Alexander City, Alabama; Dothan, Alabama; Fairhope, Alabama · 84 sites in all
- Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery DiseasePivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07318610 · 7,050 participants (planned) · Start Jul 10, 2026 · Primary completion Aug 18, 2029
Drug: REGN7508; REGN9933 and 2 more · For: Peripheral Artery Disease (PAD)
Sites: Alexander City, Alabama; Avondale, Arizona; Little Rock, Arkansas · 34 sites in all
- Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is UnsuitablePivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07430956 · 2,628 participants (planned) · Start Apr 3, 2026 · Primary completion Mar 28, 2029
Drug: REGN7508; REGN9933 and 1 more · For: Atrial Fibrillation (AF)
Sites: Dothan, Alabama; Glendale, Arizona; Little Rock, Arkansas · 45 sites in all
- REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult ParticipantsPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07213778 · 2,000 participants (planned) · Start Nov 24, 2025 · Primary completion May 17, 2027
Drug: REGN7508; Acetylsalicylic Acid (ASA) and 1 more · For: Symptomatic Venous Thromboembolism (VTE)
Sites: La Mesa, California; Rancho Mirage, California; Riverside, California · 57 sites in all
- REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in AdultsPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07015905 · 2,000 participants (planned) · Start Jun 25, 2025 · Primary completion Feb 20, 2027
Drug: REGN7508; Apixaban and 2 more · For: Venous Thromboembolism (VTE)
Sites: Sheffield, Alabama; Riverside, California; Englewood, Colorado · 47 sites in all
- Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC)Pivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07697599 · 1,908 participants (planned) · Start Sep 7, 2026 · Primary completion Jun 25, 2029
Drug: REGN7508; REGN9933 and 1 more · For: Venous Thromboembolism (VTE)
Sites: Tbilisi, Georgia
- Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic CancersPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07493304 · 1,600 participants (planned) · Start Aug 26, 2026 · Primary completion Jul 18, 2031
Drug: REGN7508; Apixaban · For: Venous Thromboembolism (VTE)
Sites: Hialeah, Florida; New York, New York; El Paso, Texas · 14 sites in all
- Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Pivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07854782 · 1,500 participants (planned) · Start Oct 28, 2026 · Primary completion Mar 3, 2029
Drug: ALN-CIDEB; Placebo · For: Metabolic Dysfunction-Associated Steatotic Liver Disease; MASLD
Sites: Miami, Florida; Marrero, Louisiana; Metairie, Louisiana · 5 sites in all
- REGN7508 in Adult Participants for Prevention of Cancer-Associated ThrombosisPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07410117 · 1,120 participants (planned) · Start Mar 9, 2026 · Primary completion Jan 23, 2030
Drug: REGN7508; Placebo · For: Cancer-Associated Thrombosis (CAT)
Sites: Hialeah, Florida; North Miami Beach, Florida; Boston, Massachusetts · 28 sites in all
- A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic AtrophyPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06541704 · 975 participants (planned) · Start Oct 30, 2024 · Primary completion Jul 31, 2028
Drug: Pozelimab; Cemdisiran and 1 more · For: Age-related Macular Degeneration (AMD); Geographic Atrophy (GA)
Sites: Chandler, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 233 sites in all
Marketed drugs (9)
Newest FDA action first.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.